Ramona Bürki
study nurse
Medizinische Onkologie und Hämatologie · Dept. I
A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
Aug 27, 2024
Clinical Studies - Aug 27, 2024 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
Apr 18, 2024
Clinical Studies - Apr 18, 2024 - Dec 31, 2099
Ongoing
Project leader: Hitz Felicitas
Members: Bürki Ramona, Quinter Janine
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Oct 30, 2023
Clinical Studies - Oct 30, 2023 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Mono-therapy and in Com-bination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)
Mar 2, 2023
Clinical Studies - Mar 2, 2023 - Oct 2, 2023
Completed
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Feb 7, 2023Zweck dieser Studie ist die Bewertung potenzieller neuer Krebstherapien für inoperable, fortgeschrittene oder metastasierte solide Tumore. Die Studie soll Informationen über Sicherheit, Verträglichkeit, die Menge des Arzneimittels bzw. der Arzneimitt...
Clinical Studies - Feb 7, 2023 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Bürki Ramona, Quinter Janine
CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS
Sep 2, 2022Diese klinische Studie wird durchgeführt, um ein neues Prüfpräparat mit der Bezeichnung "CTL-002" zu testen. CTL-002 gehört zu einer Klasse von Medikamenten, die als monoklonale Antikörper bezeichnet werden. Antikörper sind vom Immunsystem hergestell...
Clinical Studies - Sep 2, 2022 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA
Apr 20, 2022Doppel-blind, Placebo-kontrollierte, randomisierte Phase 3 Studie zur Evaluation eines zusätzlichen klinischen Benefits durch die Zugabe des CD19-Antikörpers Tafasitamab zu Rituximab-Lenalidomid bei Patienten mit rezidiviertem/refraktärem Follikuläre...
Clinical Studies - Apr 20, 2022 - Dec 31, 2025
Ongoing
Project leader: Fehr Martin
Members: Bürki Ramona
INCMOR0208-301
Apr 20, 2021A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY...
Clinical Studies - Apr 20, 2021 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Bürki Ramona, Müller Fiona